BNR
Income statement / Annual
Last year (2024), Burning Rock Biotech Limited's total revenue was $515.82 M,
a decrease of 4.02% from the previous year.
In 2024, Burning Rock Biotech Limited's net income was -$346.63 M.
See Burning Rock Biotech Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$515.82 M |
$537.44 M |
$563.24 M |
$507.86 M |
$429.90 M |
$381.68 M |
$208.87 M |
$111.17 M |
| Cost of Revenue |
$153.42 M
|
$174.21 M
|
$183.20 M
|
$143.72 M
|
$115.98 M
|
$108.34 M
|
$73.81 M
|
$39.47 M
|
| Gross Profit |
$362.40 M
|
$363.23 M
|
$380.04 M
|
$364.15 M
|
$313.92 M
|
$273.33 M
|
$135.06 M
|
$71.70 M
|
| Gross Profit Ratio |
0.7
|
0.68
|
0.67
|
0.72
|
0.73
|
0.72
|
0.65
|
0.64
|
| Research and Development Expenses |
$232.29 M
|
$347.02 M
|
$421.87 M
|
$367.86 M
|
$263.94 M
|
$156.94 M
|
$105.30 M
|
$49.02 M
|
| General & Administrative Expenses |
$261.64 M
|
$437.82 M
|
$568.28 M
|
$490.26 M
|
$293.80 M
|
$132.16 M
|
$88.30 M
|
$76.04 M
|
| Selling & Marketing Expenses |
$190.90 M
|
$247.71 M
|
$370.29 M
|
$303.10 M
|
$168.59 M
|
$153.33 M
|
$102.86 M
|
$67.51 M
|
| Selling, General & Administrative Expenses |
$452.54 M
|
$685.53 M
|
$938.58 M
|
$793.35 M
|
$462.39 M
|
$285.49 M
|
$191.16 M
|
$143.54 M
|
| Other Expenses |
$35.13 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$488.00 K
|
-$32.00 K
|
| Operating Expenses |
$719.96 M
|
$1.03 B
|
$1.36 B
|
$1.16 B
|
$726.33 M
|
$442.43 M
|
$296.46 M
|
$192.56 M
|
| Cost And Expenses |
$873.38 M
|
$1.21 B
|
$1.54 B
|
$1.30 B
|
$842.31 M
|
$550.77 M
|
$370.26 M
|
$232.03 M
|
| Interest Income |
$12.21 M
|
$17.96 M
|
$9.46 M
|
$3.46 M
|
$6.07 M
|
$11.16 M
|
$1.34 M
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$1.54 M
|
$667.00 K
|
$8.99 M
|
$17.95 M
|
$9.86 M
|
| Depreciation & Amortization |
$52.20 M
|
$133.40 M
|
$124.10 M
|
$47.77 M
|
$33.31 M
|
$31.36 M
|
$24.68 M
|
$21.31 M
|
| EBITDA |
-$270.23 M |
-$517.90 M |
-$856.31 M |
-$746.50 M |
-$373.26 M |
-$128.81 M |
-$135.87 M |
-$99.55 M |
| EBITDA Ratio |
-0.52
|
-0.96
|
-1.52
|
-1.47
|
-0.87
|
-0.34
|
-0.65
|
-0.9
|
| Operating Income Ratio |
-0.69
|
-1.25
|
-1.74
|
-1.57
|
-0.96
|
-0.44
|
-0.77
|
-1.09
|
| Total Other Income/Expenses Net |
$16.82 M
|
$18.02 M
|
$11.16 M
|
$1.27 M
|
$5.17 M
|
-$64.00 K
|
-$16.10 M
|
-$10.41 M
|
| Income Before Tax |
-$340.74 M
|
-$651.30 M
|
-$969.25 M
|
-$795.80 M
|
-$407.24 M
|
-$169.16 M
|
-$177.50 M
|
-$131.28 M
|
| Income Before Tax Ratio |
-0.66
|
-1.21
|
-1.72
|
-1.57
|
-0.95
|
-0.44
|
-0.85
|
-1.18
|
| Income Tax Expense |
$5.89 M
|
$2.39 M
|
$1.99 M
|
$899.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$346.63 M
|
-$653.69 M
|
-$971.23 M
|
-$796.70 M
|
-$407.24 M
|
-$168.34 M
|
-$177.50 M
|
-$131.28 M
|
| Net Income Ratio |
-0.67
|
-1.22
|
-1.72
|
-1.57
|
-0.95
|
-0.44
|
-0.85
|
-1.18
|
| EPS |
-33.67 |
-63.84 |
-93.47 |
-76.45 |
-68.76 |
-142.3 |
-103.82 |
-102.02 |
| EPS Diluted |
-33.67 |
-63.84 |
-93.47 |
-76.45 |
-68.76 |
-142.3 |
-103.82 |
-102.02 |
| Weighted Average Shares Out |
$10.29 M
|
$10.24 M
|
$10.39 M
|
$10.42 M
|
$5.92 M
|
$1.19 M
|
$1.71 M
|
$1.29 M
|
| Weighted Average Shares Out Diluted |
$10.29 M
|
$10.24 M
|
$10.39 M
|
$10.42 M
|
$6.86 M
|
$2.35 M
|
$2.24 M
|
$1.81 M
|
| Link |
|
|
|
|
|
|
|
|
